How to prepare foreign labeling for an FDA submission

How should foreign labeling be presented in an FDA submission?

Identify the exact jurisdiction, product, authorization status, original version and source. Pair the original with the corresponding reviewed translation, explain the US submission question it addresses and describe material product or indication differences. Keep foreign approval, proposed text and company core information distinct. Including a label does not replace an independently applicable foreign-experience or marketing-development report.

Before you begin

Document preparation for foreign labeling requested or relevant in a US dossier. The electronic heading alone does not make every foreign label mandatory or turn foreign approval into US authorization.

What you will prepare: A source-authenticated foreign-label record, appropriate translation and a clear explanation of relevance and differences.

Establish jurisdiction and actual status

Record country or authority, product, authorization identifier, language, labeling version and its source. Distinguish approved text from proposed changes, company core information and marketing material. Obtain the original from the responsible regulatory affiliate or authoritative record. If approval status is unknown, label it unknown and request evidence; a translated company file is not proof of authorization.

Preserve meaning and provenance

Provide the original and the translation needed for the review task, with a documented relationship between them. Use a qualified review process for scientific terminology, doses, units, warnings and legal status. Identify untranslated portions and ambiguous terms. Do not silently harmonize a foreign indication with the proposed US indication: the difference may be exactly what FDA needs to understand.

Explain relevance without importing another authority’s decision

State the agency request or dossier question the material addresses. Compare the product and population with the US submission and identify material differences. The IND framework separately addresses relevant foreign experience and significant foreign marketing developments; filing a foreign label does not discharge every related reporting obligation. Likewise, an NDA labeling proposal requires its own support rather than a statement that another jurisdiction approved it.

Fictional example: two similar-looking versions

The affiliate supplies a draft translation while the original is an older approved label. Stop the pair from being described as one approved record. Obtain the matching source or mark the proposal separately. If the jurisdiction’s route or formulation differs, explain that difference and reassess how much the document supports the FDA question.

Create a paired-version record and a separate relevance assessment

A translated label is useful only if the reviewer can establish what it represents. Build the identity record before writing a comparison with US text. These fields are a proposed preparation aid, not a universal agency translation template.

Keep the approval date, label revision date, effective date and date obtained separate where those events are known. An affiliate's delivery date is not proof of when a change became authorized. If a date or status cannot be established, mark that specific field unresolved and request the supporting record. Do not convert an unknown status into either “approved” or “not approved.”

For a translation review, compare every safety-critical number and unit with its source, including decimal separators, concentration versus total quantity and frequency language. Preserve the meaning of a restriction or contraindication rather than replacing it with preferred US phrasing. Record ambiguous terminology for a qualified decision. The need for a particular certified translation or attestation depends on the actual submission context; these cited provisions do not create one universal certification rule for every foreign label.

Fictional comparison exercise: a foreign product uses the same brand name but a different concentration and a narrower population than the proposed US product. The initial summary calls the labels equivalent. Rebuild the comparison using the exact product records, retain the concentration and population differences, and explain what the foreign document does and does not establish for the FDA question. Changing the translated numbers or broadening the translated population to make the columns match would destroy the evidence being submitted.

In an IND, 312.23(a)(3)(ii) addresses relevant prior human experience, including foreign investigational or marketing experience. Paragraph (iii) separately addresses withdrawal from investigation or marketing in any country for safety- or effectiveness-related reasons, including the countries and reasons. Section 312.33(f) addresses significant foreign marketing developments during the annual-report period, with approval, withdrawal and suspension as examples. Assess those obligations on their own facts; attaching a foreign label is not an equivalent narrative or a reason to defer another applicable safety report.

Use the US draft-label guide for the separately supported US proposal and the IND annual-report guide for that reporting task. The foreign-label record preserves another jurisdiction's evidence and status; it does not make this an instruction for filing Module 1 with that authority.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides